Steven F. Bellon
Chief Scientific OfficerDr. Steven F. Bellon, Ph.D., serves as Chief Scientific Officer of Foghorn Therapeutics Inc. since January 10, 2022 and served as Senior Vice President of Drug Discovery since October 2019 until January 10, 2022. Dr. Bellon previously served in the role of Vice President, Drug Discovery since June 2016. Prior to joining Foghorn, Dr. Bellon was Senior Director and Executive Director of Constellation Pharmaceuticals, starting in September 2008. At Constellation Pharmaceuticals, Dr. Bellon built the structural biology group and the bromodomain platform. Dr. Bellon has also held positions at Amgen and Vertex Pharmaceuticals and has rich experience in drug discovery. Dr. Bellon joined Foghorn Therapeutics in 2016 as head of drug discovery, bringing drug discovery experience from multiple drug classes. During his tenure at Foghorn, he has been instrumental in building Foghorn’s Gene Traffic Control® platform and advancing the Company’s broad therapeutic pipeline of over 15 programs including protein degraders, enzymatic inhibitors and transcription factor disruptors. He was head of structural biology, and lead discovery and project management at Constellation Pharmaceuticals. He has a passion for drugging novel targets and has contributed to many drug discovery efforts in oncology including those for p38, HCV helicase, cMet, BET, EZH2, and numerous bromodomains. He completed postdoctoral training at Yale University. Dr. Bellon received his B.S. from Haverford College and his Ph.D. in physical chemistry from the Massachusetts Institute of Technology.
Positions
- Company NameFoghorn Therapeutics Inc.Stock CodeFHTXPositionChief Scientific OfficerColleagues
